Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$440.87
-7.53-1.68%
At close: -
$440.87
0.000.00%
After Hours: Jun 20, 4:04 PM EDT
Comments
Loading...
Vertex Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:VRTX | Benzinga
Vertex Pharmaceuticals Inc has a consensus price target of $512.13 based on the ratings of 28 analysts. The high is $583 issued by UBS on February 11, 2025. The low is $420 issued by RBC Capital on June 17, 2025. The 3 most-recent analyst ratings were released by Morgan Stanley, RBC Capital, and RBC Capital on June 20, 2025, June 17, 2025, and May 6, 2025, respectively. With an average price target of $434.33 between Morgan Stanley, RBC Capital, and RBC Capital, there's an implied -1.48% downside for Vertex Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Morgan Stanley
RBC Capital
Scotiabank
JP Morgan
Cantor Fitzgerald
1calculated from analyst ratings
Analyst Ratings for Vertex Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/20/2025 | Buy Now | 4.34% | Morgan Stanley | Matthew Harrison61% | $464 → $460 | Maintains | Equal-Weight | Get Alert |
| 06/17/2025 | Buy Now | -4.73% | RBC Capital | Brian Abrahams49% | $423 → $420 | Maintains | Sector Perform | Get Alert |
| 05/06/2025 | Buy Now | -4.05% | RBC Capital | Brian Abrahams49% | $420 → $423 | Maintains | Sector Perform | Get Alert |
| 05/06/2025 | Buy Now | 0.26% | Scotiabank | Greg Harrison47% | $450 → $442 | Maintains | Sector Perform | Get Alert |
| 05/06/2025 | Buy Now | 5.25% | Morgan Stanley | Matthew Harrison61% | $462 → $464 | Maintains | Equal-Weight | Get Alert |
| 05/06/2025 | Buy Now | 16.81% | JP Morgan | Jessica Fye67% | $512 → $515 | Maintains | Overweight | Get Alert |
| 05/06/2025 | Buy Now | 21.35% | Cantor Fitzgerald | Carter Gould56% | $535 → $535 | Reiterates | Overweight → Overweight | Get Alert |
| 05/06/2025 | Buy Now | — | Needham | Joseph Stringer44% | — | Reiterates | Hold → Hold | Get Alert |
| 05/06/2025 | Buy Now | 14.09% | Leerink Partners | David Risinger72% | $550 → $503 | Downgrade | Outperform → Market Perform | Get Alert |
| 04/22/2025 | Buy Now | 21.35% | Cantor Fitzgerald | Carter Gould56% | → $535 | Assumes | → Overweight | Get Alert |
| 04/01/2025 | Buy Now | -4.73% | RBC Capital | Brian Abrahams49% | $408 → $420 | Maintains | Sector Perform | Get Alert |
| 03/31/2025 | Buy Now | 28.61% | B of A Securities | Ying Huang58% | $555 → $567 | Maintains | Buy | Get Alert |
| 02/20/2025 | Buy Now | -7.46% | RBC Capital | Brian Abrahams49% | $407 → $408 | Maintains | Sector Perform | Get Alert |
| 02/12/2025 | Buy Now | -3.83% | Canaccord Genuity | Whitney Ijem58% | $408 → $424 | Upgrade | Sell → Hold | Get Alert |
| 02/11/2025 | Buy Now | 32.24% | UBS | Colin Bristow40% | $586 → $583 | Maintains | Buy | Get Alert |
| 02/11/2025 | Buy Now | 25.89% | B of A Securities | Ying Huang58% | $540 → $555 | Maintains | Buy | Get Alert |
| 02/11/2025 | Buy Now | 17.95% | Truist Securities | Joon Lee77% | $460 → $520 | Maintains | Buy | Get Alert |
| 02/11/2025 | Buy Now | -7.68% | RBC Capital | Brian Abrahams49% | $402 → $407 | Maintains | Sector Perform | Get Alert |
| 02/11/2025 | Buy Now | 2.07% | Scotiabank | Greg Harrison47% | $433 → $450 | Maintains | Sector Perform | Get Alert |
| 02/11/2025 | Buy Now | 8.88% | Cantor Fitzgerald | Olivia Brayer53% | $480 → $480 | Reiterates | Overweight → Overweight | Get Alert |
| 02/11/2025 | Buy Now | 5.93% | Barclays | Gena Wang51% | $435 → $467 | Maintains | Equal-Weight | Get Alert |
| 02/11/2025 | Buy Now | 24.75% | HC Wainwright & Co. | Andrew Fein45% | $550 → $550 | Reiterates | Buy → Buy | Get Alert |
| 02/11/2025 | Buy Now | 4.11% | Morgan Stanley | Matthew Harrison61% | $450 → $459 | Maintains | Equal-Weight | Get Alert |
| 02/11/2025 | Buy Now | — | Needham | Joseph Stringer44% | — | Reiterates | Hold → Hold | Get Alert |
| 02/04/2025 | Buy Now | 22.49% | B of A Securities | Ying Huang58% | $522 → $540 | Maintains | Buy | Get Alert |
| 01/31/2025 | Buy Now | -1.33% | Barclays | Gena Wang51% | $418 → $435 | Maintains | Equal-Weight | Get Alert |
| 01/31/2025 | Buy Now | 23.62% | BMO Capital | Evan Seigerman63% | $520 → $545 | Maintains | Outperform | Get Alert |
| 01/31/2025 | Buy Now | 8.88% | Cantor Fitzgerald | Olivia Brayer53% | $480 → $480 | Reiterates | Overweight → Overweight | Get Alert |
| 01/31/2025 | Buy Now | -1.79% | Scotiabank | Greg Harrison47% | $430 → $433 | Maintains | Sector Perform | Get Alert |
| 01/31/2025 | Buy Now | 24.75% | HC Wainwright & Co. | Andrew Fein45% | $535 → $550 | Maintains | Buy | Get Alert |
| 01/31/2025 | Buy Now | — | Needham | Joseph Stringer44% | — | Reiterates | Hold → Hold | Get Alert |
| 01/30/2025 | Buy Now | 4.34% | Wells Fargo | Mohit Bansal67% | $460 → $460 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 01/27/2025 | Buy Now | 20.9% | Piper Sandler | Christopher Raymond55% | $535 → $533 | Maintains | Overweight | Get Alert |
| 01/24/2025 | Buy Now | 8.88% | Cantor Fitzgerald | Olivia Brayer53% | $480 → $480 | Reiterates | Overweight → Overweight | Get Alert |
| 01/10/2025 | Buy Now | 4.34% | Wells Fargo | Mohit Bansal67% | $555 → $460 | Maintains | Overweight | Get Alert |
| 12/23/2024 | Buy Now | 4.34% | Truist Securities | Joon Lee77% | $550 → $460 | Maintains | Buy | Get Alert |
| 12/23/2024 | Buy Now | -2.47% | Scotiabank | Greg Harrison47% | $426 → $430 | Maintains | Sector Perform | Get Alert |
| 12/23/2024 | Buy Now | 13.41% | JP Morgan | Jessica Fye67% | $503 → $500 | Maintains | Overweight | Get Alert |
| 12/20/2024 | Buy Now | -5.19% | Barclays | Gena Wang51% | $509 → $418 | Maintains | Equal-Weight | Get Alert |
| 12/20/2024 | Buy Now | 17.95% | BMO Capital | Evan Seigerman63% | $566 → $520 | Maintains | Outperform | Get Alert |
| 12/20/2024 | Buy Now | — | Needham | Joseph Stringer44% | — | Reiterates | Hold → Hold | Get Alert |
| 12/20/2024 | Buy Now | 21.35% | HC Wainwright & Co. | Andrew Fein45% | $600 → $535 | Maintains | Buy | Get Alert |
| 12/19/2024 | Buy Now | — | Oppenheimer | Hartaj Singh45% | — | Downgrade | Outperform → Perform | Get Alert |
| 12/19/2024 | Buy Now | 18.4% | B of A Securities | Ying Huang58% | $545 → $522 | Maintains | Buy | Get Alert |
| 12/16/2024 | Buy Now | 12.05% | Stifel | Paul Matteis44% | $490 → $494 | Maintains | Hold | Get Alert |
| 12/09/2024 | Buy Now | 24.75% | Jefferies | Michael Yee56% | $500 → $550 | Upgrade | Hold → Buy | Get Alert |
| 11/14/2024 | Buy Now | 30.42% | Citigroup | Geoff Meacham63% | → $575 | Initiates | → Buy | Get Alert |
| 11/06/2024 | Buy Now | -7.46% | Canaccord Genuity | Whitney Ijem58% | $361 → $408 | Maintains | Sell | Get Alert |
| 11/05/2024 | Buy Now | 10.24% | Scotiabank | Greg Harrison47% | $480 → $486 | Maintains | Sector Perform | Get Alert |
| 11/05/2024 | Buy Now | 32.92% | UBS | Colin Bristow40% | $562 → $586 | Maintains | Buy | Get Alert |
| 11/05/2024 | Buy Now | 8.88% | Cantor Fitzgerald | Olivia Brayer53% | $480 → $480 | Reiterates | Overweight → Overweight | Get Alert |
| 11/05/2024 | Buy Now | 2.3% | RBC Capital | Brian Abrahams49% | $437 → $451 | Maintains | Sector Perform | Get Alert |
| 11/05/2024 | Buy Now | 14.09% | JP Morgan | Jessica Fye67% | $510 → $503 | Maintains | Overweight | Get Alert |
| 11/05/2024 | Buy Now | 7.97% | Morgan Stanley | Matthew Harrison61% | $473 → $476 | Maintains | Equal-Weight | Get Alert |
| 10/30/2024 | Buy Now | 22.49% | Oppenheimer | Hartaj Singh45% | $550 → $540 | Maintains | Outperform | Get Alert |
| 10/21/2024 | Buy Now | 36.09% | HC Wainwright & Co. | Andrew Fein45% | $600 → $600 | Reiterates | Buy → Buy | Get Alert |
| 10/17/2024 | Buy Now | 27.48% | UBS | Colin Bristow40% | $477 → $562 | Maintains | Buy | Get Alert |
| 10/16/2024 | Buy Now | 8.88% | Scotiabank | Greg Harrison47% | → $480 | Initiates | → Sector Perform | Get Alert |
| 10/14/2024 | Buy Now | 22.71% | B of A Securities | Ying Huang58% | $550 → $541 | Maintains | Buy | Get Alert |
| 10/10/2024 | Buy Now | — | Raymond James | Danielle Brill42% | — | Reinstates | → Market Perform | Get Alert |
| 10/09/2024 | Buy Now | -0.88% | RBC Capital | Brian Abrahams49% | $425 → $437 | Maintains | Sector Perform | Get Alert |
| 10/08/2024 | Buy Now | 8.88% | Cantor Fitzgerald | Olivia Brayer53% | $480 → $480 | Reiterates | Overweight → Overweight | Get Alert |
| 10/04/2024 | Buy Now | -3.6% | RBC Capital | Brian Abrahams49% | $431 → $425 | Maintains | Sector Perform | Get Alert |
| 10/01/2024 | Buy Now | 7.51% | Morgan Stanley | Matthew Harrison61% | $462 → $474 | Maintains | Equal-Weight | Get Alert |
| 09/19/2024 | Buy Now | -2.24% | RBC Capital | Brian Abrahams49% | $431 → $431 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 08/05/2024 | Buy Now | 36.09% | HC Wainwright & Co. | Andrew Fein45% | $500 → $600 | Maintains | Buy | Get Alert |
| 08/05/2024 | Buy Now | 24.75% | Oppenheimer | Hartaj Singh45% | $500 → $550 | Maintains | Outperform | Get Alert |
| 08/05/2024 | Buy Now | 15.68% | JP Morgan | Jessica Fye67% | $505 → $510 | Maintains | Overweight | Get Alert |
| 08/05/2024 | Buy Now | 24.75% | Truist Securities | Joon Lee77% | $508 → $550 | Reiterates | Buy → Buy | Get Alert |
| 08/05/2024 | Buy Now | 15.45% | Barclays | Gena Wang51% | $472 → $509 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 08/02/2024 | Buy Now | 16.81% | Evercore ISI Group | Liisa Bayko42% | $438 → $515 | Maintains | Outperform | Get Alert |
| 08/02/2024 | Buy Now | 26.57% | Guggenheim | Debjit Chattopadhyay54% | $450 → $558 | Maintains | Buy | Get Alert |
| 08/02/2024 | Buy Now | 8.88% | Cantor Fitzgerald | Olivia Brayer53% | $480 → $480 | Reiterates | Overweight → Overweight | Get Alert |
| 08/02/2024 | Buy Now | 21.35% | Piper Sandler | Christopher Raymond55% | $500 → $535 | Maintains | Overweight | Get Alert |
| 07/31/2024 | Buy Now | -14.71% | Canaccord Genuity | Whitney Ijem58% | $371 → $376 | Maintains | Sell | Get Alert |
| 07/26/2024 | Buy Now | — | Needham | Joseph Stringer44% | — | Reiterates | → Hold | Get Alert |
| 07/23/2024 | Buy Now | 13.41% | TD Cowen | Phil Nadeau66% | $450 → $500 | Maintains | Buy | Get Alert |
| 07/22/2024 | Buy Now | 8.88% | Cantor Fitzgerald | Olivia Brayer53% | $440 → $480 | Maintains | Overweight | Get Alert |
| 07/19/2024 | Buy Now | 13.41% | HC Wainwright & Co. | Andrew Fein45% | $462 → $500 | Maintains | Buy | Get Alert |
| 07/11/2024 | Buy Now | 3.21% | Morgan Stanley | Matthew Harrison61% | $402 → $455 | Maintains | Equal-Weight | Get Alert |
| 06/27/2024 | Buy Now | 23.62% | Redburn Atlantic | Steve Chesney54% | → $545 | Initiates | → Buy | Get Alert |
| 06/24/2024 | Buy Now | 25.89% | Wells Fargo | Mohit Bansal67% | $540 → $555 | Maintains | Overweight | Get Alert |
| 06/17/2024 | Buy Now | 24.75% | Argus Research | Jasper Hellweg68% | $465 → $550 | Maintains | Buy | Get Alert |
| 06/11/2024 | Buy Now | -4.51% | RBC Capital | Brian Abrahams49% | $424 → $421 | Maintains | Sector Perform | Get Alert |
| 06/04/2024 | Buy Now | -3.83% | RBC Capital | Brian Abrahams49% | $424 → $424 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 05/31/2024 | Buy Now | 13.41% | BMO Capital | Evan Seigerman63% | $480 → $500 | Maintains | Outperform | Get Alert |
| 05/07/2024 | Buy Now | 4.79% | HC Wainwright & Co. | Andrew Fein45% | $462 → $462 | Reiterates | Buy → Buy | Get Alert |
| 05/07/2024 | Buy Now | -3.83% | RBC Capital | Brian Abrahams49% | $417 → $424 | Maintains | Sector Perform | Get Alert |
| 05/07/2024 | Buy Now | 3.43% | Piper Sandler | Christopher Raymond55% | $450 → $456 | Maintains | Overweight | Get Alert |
| 05/07/2024 | Buy Now | — | Needham | Joseph Stringer44% | — | Reiterates | → Hold | Get Alert |
| 04/18/2024 | Buy Now | 2.07% | Guggenheim | Debjit Chattopadhyay54% | $445 → $450 | Maintains | Buy | Get Alert |
| 04/17/2024 | Buy Now | 5.7% | UBS | Colin Bristow40% | $498 → $466 | Maintains | Buy | Get Alert |
| 04/15/2024 | Buy Now | 13.41% | Oppenheimer | Hartaj Singh45% | → $500 | Maintains | Outperform | Get Alert |
| 04/12/2024 | Buy Now | -15.85% | Canaccord Genuity | Whitney Ijem58% | $371 → $371 | Maintains | Sell | Get Alert |
| 04/11/2024 | Buy Now | 4.79% | HC Wainwright & Co. | Andrew Fein45% | $457 → $462 | Maintains | Buy | Get Alert |
| 04/11/2024 | Buy Now | -0.65% | Evercore ISI Group | Liisa Bayko42% | → $438 | Upgrade | In-Line → Outperform | Get Alert |
| 02/20/2024 | Buy Now | -0.2% | Cantor Fitzgerald | Olivia Brayer53% | $440 → $440 | Reiterates | Overweight → Overweight | Get Alert |
| 02/15/2024 | Buy Now | — | Wolfe Research | Andy Chen48% | — | Initiates | → Outperform | Get Alert |
| 02/06/2024 | Buy Now | -0.2% | Cantor Fitzgerald | Olivia Brayer53% | $440 → $440 | Reiterates | Overweight → Overweight | Get Alert |
| 02/06/2024 | Buy Now | 2.07% | JP Morgan | Jessica Fye67% | $438 → $450 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Vertex Pharmaceuticals (VRTX) stock?
The latest price target for Vertex Pharmaceuticals (NASDAQ:VRTX) was reported by Morgan Stanley on June 20, 2025. The analyst firm set a price target for $460.00 expecting VRTX to rise to within 12 months (a possible 4.34% upside). 82 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Vertex Pharmaceuticals (VRTX)?
The latest analyst rating for Vertex Pharmaceuticals (NASDAQ:VRTX) was provided by Morgan Stanley, and Vertex Pharmaceuticals maintained their equal-weight rating.
When was the last upgrade for Vertex Pharmaceuticals (VRTX)?
The last upgrade for Vertex Pharmaceuticals Inc happened on February 12, 2025 when Canaccord Genuity raised their price target to $424. Canaccord Genuity previously had a sell for Vertex Pharmaceuticals Inc.
When was the last downgrade for Vertex Pharmaceuticals (VRTX)?
The last downgrade for Vertex Pharmaceuticals Inc happened on May 6, 2025 when Leerink Partners changed their price target from $550 to $503 for Vertex Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Vertex Pharmaceuticals (VRTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vertex Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vertex Pharmaceuticals was filed on June 20, 2025 so you should expect the next rating to be made available sometime around June 20, 2026.
Is the Analyst Rating Vertex Pharmaceuticals (VRTX) correct?
While ratings are subjective and will change, the latest Vertex Pharmaceuticals (VRTX) rating was a maintained with a price target of $464.00 to $460.00. The current price Vertex Pharmaceuticals (VRTX) is trading at is $440.87, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
